Table of Contents Author Guidelines Submit a Manuscript
Journal of Analytical Methods in Chemistry
Volume 2014, Article ID 638951, 10 pages
http://dx.doi.org/10.1155/2014/638951
Research Article

A Stability-Indicating HPLC-DAD Method for Determination of Stiripentol: Development, Validation, Kinetics, Structure Elucidation and Application to Commercial Dosage Form

1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
2Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt
3Department of Medicinal and Pharmaceutical Chemistry, Pharmaceutical and Drug Industries Research Division, National Research Centre, Dokki, Giza 12622, Egypt

Received 24 August 2014; Accepted 25 September 2014; Published 14 October 2014

Academic Editor: Josep Esteve-Romero

Copyright © 2014 Hany W. Darwish et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. K. Trojnar, K. Wojtal, M. P. Trojnar, and S. J. Czuczwar, “Stiripentol. A novel antiepileptic drug,” Pharmacological Reports, vol. 57, no. 2, pp. 154–160, 2005. View at Google Scholar · View at Scopus
  2. J. N. Lisgarten and R. A. Palmer, “The structure of stiripentol: 4,4 dimethyl- 1-(3,4-methylenedioxyphenyl)-1-penten-3-ol-a novel antiepileptic drug,” Acta Crystallographica, Section C: Crystal Structure Communications, vol. 44, pp. 1992–1994, 1988. View at Publisher · View at Google Scholar · View at Scopus
  3. D. F. Chollet, “Determination of antiepileptic drugs in biological material,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 767, no. 2, pp. 191–233, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. D. D. Shen, R. Levy, J. L. Savitch, A. V. Boddy, F. Tombret, and F. Lepage, “Comparative anticonvulsant potency and pharmacokinetics of (+)- and (−)-enantiomers of stiripentol,” Epilepsy Research, vol. 12, no. 1, pp. 29–36, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. M. F. El-Behairy and E. Sundby, “Synthesis of the antiepileptic (R)-stiripentol by a combination of lipase catalyzed resolution and alkene metathesis,” Tetrahedron Asymmetry, vol. 24, no. 5-6, pp. 285–289, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Lin, R. Levy, H. Blehaut, J. Tor, and R. Levy, “Pharmacokinetic properties and metabolic profile of stiripentol in primates,” in Metabolism of Antiepileptic Drugs, pp. 199–207, Raven Press, New York, NY, USA, 1984. View at Google Scholar
  7. H. S. Lin and R. H. Levy, “Pharmacokinetic profile of a new anticonvulsant, stiripentol, in the rhesus monkey,” Epilepsia, vol. 24, no. 6, pp. 692–702, 1983. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Fisher, “The effects of stiripentol on GABAA receptors,” Epilepsia, vol. 52, no. 2, pp. 76–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. E. C. Wirrell, L. Laux, D. N. Franz et al., “Stiripentol in Dravet syndrome: results of a retrospective US study,” Epilepsia, vol. 54, no. 9, pp. 1595–1604, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. European Medicines Agency, “Stiripentol: Scientific Discussion,” http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000664/WC500036521.pdf.
  11. M. Poisson, F. Huguet, A. Savattier, F. Bakri-Logeais, and G. Narcisse, “A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study,” Arzneimittel-Forschung, vol. 34, no. 2, pp. 199–204, 1984. View at Google Scholar · View at Scopus
  12. R. Wegmann, A. Ilies, M. Aurousseau, and F. Patte, “Pharmaco-cellular enzymology of the mode of action of the stiripentol during the cardiazolic epilepsy. III. The metabolism of lipids, proteins, nucleoproteins and proteoglycans,” Cellular and Molecular Biology, vol. 23, no. 4, pp. 455–480, 1978. View at Google Scholar · View at Scopus
  13. P. P. Quilichini, C. Chiron, Y. Ben-Ari, and H. Gozlan, “Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels,” Epilepsia, vol. 47, no. 4, pp. 704–716, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. The United States Pharmacopeia (USP) 24th version, United States Pharmacopeial Convention, Rochville, Md, USA, 2000.
  15. ICH Guidance for Industry, Q1A (R2): Stability Testing of New Drug Substances and Products (Revision 2), U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Rockville, Md, USA, 2003.
  16. S. Ahuja and K. M. Alsante, Handbook of Isolation and Characterization of Impurities in Pharmaceuticals, Academic Press, San Diego, Calif, USA, 2003.
  17. FDA, Guidance for Industry: Impurities in Drug Product, Draft Guidance, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 1998.
  18. R. H. Arends, K. Zhang, R. H. Levy, T. A. Baillie, and D. D. Shen, “Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect,” Epilepsy Research, vol. 18, no. 2, pp. 91–96, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. E. E. Jacobsen, T. Anthonsen, M. F. El-Behairy et al., “Lipase catalysed kinetic resolution of stiripentol,” International Journal of Chemistry, vol. 4, no. 1, p. 7, 2012. View at Google Scholar
  20. M. Machin, A. Idoate, R. Mangues, I. Castro, C. Martinez, and J. Giraldez, “Determination of plasma stiripentol liquid chromatography for high resolution,” Journal of the Spanish Association of Hospital Pharmacists, vol. 12, pp. 197–201, 1988. View at Google Scholar